Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi XDC CaymanSTU:L74 -5.06%50 Return-on-Tangible-Asset is 12.00% as of Dec. 2025, which is 10% above its 10-year median of 10.91. GuruFocus rates STU:L74 with a GF Score™ of 50/100. The stock has 3 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, WuXi XDC Cayman ranks better than 84.11% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. WuXi XDC Cayman's annualizedNet Income for the quarter that ended in Dec. 2025 was €178.2 Mil. WuXi XDC Cayman's average total tangible assets for the quarter that ended in Dec. 2025 was €1,484.5 Mil. Therefore, WuXi XDC Cayman's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 12.00%.
The historical rank and industry rank for WuXi XDC Cayman's Return-on-Tangible-Asset or its related term are showing as below:
STU:L74'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 6.48 Med: 10.91 Max: 13.81
Current: 12.25
During the past 6 years, WuXi XDC Cayman's highest Return-on-Tangible-Asset was 13.81%. The lowest was 6.48%. And the median was 10.91%.
STU:L74's Return-on-Tangible-Asset is ranked better than 84.11% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.715
vs STU:L74: 12.25
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
WuXi XDC Cayman Return-on-Tangible-Asset Related Terms
WuXi XDC Cayman Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for WuXi XDC Cayman's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:L74 vs TMO, DHR, NTRA: Return-on-Tangible-Asset Comparison
For the Diagnostics & Research subindustry, WuXi XDC Cayman's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi XDC Cayman Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where WuXi XDC Cayman's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 12.00% mean?
WuXi XDC Cayman (STU:L74) has a Return-on-Tangible-Asset of 12.00% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on WuXi XDC Cayman and its competitors. This is 10% above median its historical median of 10.91. Over the past decade, WuXi XDC Cayman's Return-on-Tangible-Asset has ranged from 6.48 to 13.81. According to the industry distribution chart, WuXi XDC Cayman ranks #34 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 15.9%.
Is WuXi XDC Cayman's Return-on-Tangible-Asset too high?
WuXi XDC Cayman's current Return-on-Tangible-Asset of 12.00% is 10% above median its 10-year median of 10.91. Over the past 10 years, this metric has ranged from a low of 6.48 to a high of 13.81. Based on the distribution chart, WuXi XDC Cayman ranks #34 out of 214 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, WuXi XDC Cayman has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does WuXi XDC Cayman's Return-on-Tangible-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, WuXi XDC Cayman ranks #34 out of 214 companies for Return-on-Tangible-Asset. This places WuXi XDC Cayman in the top 16% of its industry — outperforming the majority of peers. Historically, WuXi XDC Cayman's own Return-on-Tangible-Asset has ranged from 6.48 to 13.81 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on WuXi XDC Cayman and its competitors. WuXi XDC Cayman's current Return-on-Tangible-Asset is 12.00%, which is 10% above median its own 10-year median of 10.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi XDC Cayman stock overvalued right now?
WuXi XDC Cayman (STU:L74) has a current Return-on-Tangible-Asset of 12.00%. The current Return-on-Tangible-Asset is 12.00%, which is 10% above median its 10-year median of 10.91. WuXi XDC Cayman's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For WuXi XDC Cayman (STU:L74), the current Return-on-Tangible-Asset is 12.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.
50GF Score
Get the complete analysis for STU:L74
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:L74 has been successfully added to your 
